不同辅助化疗方案治疗结肠癌的疗效比较  

Comparison of different adjuvant chemotherapy regimens in the treatment of colon cancer

作　　者：贝宴屏 张欢乐[1] 陆妙珍[1] 

机构地区：[1]宁波市医疗中心李惠利医院放疗科,浙江宁波315040

出　　处：《中国现代医生》2017年第6期82-84,88,共4页China Modern Doctor

基　　金：宁波市科技计划项目(2014A610223)

摘　　要：目的比较XELOX、FOLFOX不同辅助化疗方案治疗结肠癌的疗效。方法选取2015年1月~2016年1月我院应用不同化疗方案治疗的结肠癌根治术患者60例,术前均经结肠镜病理检查及核磁共振等影像学检查确诊,均行结肠癌根治术,入选患者根据化疗方案不同随机分为FOLFOX4化疗组和XELOX化疗组,每组30例,比较两组的临床总有效率及毒副反应。结果 XELOX化疗组、FOLFOX4化疗组治疗后的总有效率分别为70.0%、66.7%,组间比较,差异无显著性(P>0.05)。两组患者出现的毒副反应主要包括白细胞减少、中性粒细胞减少、血小板减少、神经毒性、恶心呕吐、腹泻、口腔炎、手足综合征、转氨酶升高、胆红素升高等。其中XELOX化疗组白细胞减少发生率30.0%(9/30),显著低于FOLFOX4化疗组的60.0%(18/30),中性粒细胞减少发生率达33.3%(10/30),显著低于FOLFOX4化疗组的50.0%(15/30),余并发症比较差异不显著。结论应用XELOX,FOLFOX不同辅助化疗方案治疗结肠癌均具有较好的疗效,但XELOX化疗方案毒副反应少,更适合于骨髓储备功能不良、耐受性差的结肠癌患者。Objective To compare the efficacy of different adjuvant chemotherapy regimens of XELOX and FOLFOX in the treatment of colon cancer. Methods 60 patients treated with colon cancer radical resection by application of different chemotherapy regimens from January 2015 to January 2016 were chosen.All patients were diagnosed by colonoscopy and magnetic resonance imaging before operation and underwent colon cancer radical surgery.The patients were ran- domly divided into FOLFOX4 chemotherapy group and XELOX chemotherapy group, with 30 cases in each group.Clini- ca｜ total efficiency and toxicity between the two groups were compared. Results The total effective rate of XEEOX chemotherapy group and FOLFOX4 chemotherapy group after treatment was 70.0% and 66.7% respectively. There was no significant difference between the two groups （P〉O.05）. Toxic side effects in two groups mainly included leukopenia, neutropenia, thrombocytopenia, neurotoxicity, nausea and vomiting, diarrhea, stomatitis, hand and foot syndrome, elevated transaminase, bilirubin and so on. The incidence of leukopenia in XELOX chemotherapy group was 30.0% （9/30）, which was significantly lower than 60.0%（18/30） in FOLFOX4 chemotherapy group. And the incidence of neutropenia was 33.3% （10/30） in XELOX chemotherapy group, significantly lower than 50.0%（15/30） in FOLFOX4 chemotherapy group. There were no significant differences in the remaining complications between the two groups. Conclusion XELOX and FOLFOX adjuvant chemotherapy regimens both have good therapeutic effects in the treatment of colorectal cancer. However, XELOX chemotherapy regimen has less toxic side effects,which is more suitable for patients with bone mar- row reserve dysfunction and poor tolerance of colon cancer.

关 键 词：结肠癌 结肠癌根治术 XELOX化疗方案 FOLFOX化疗方案 

分 类 号：R735.35[医药卫生—肿瘤]